Tandem Diabetes Care Inc. (TNDM)

7.51
0.16 2.20
NASDAQ : Health Technology
Prev Close 7.35
Open 7.32
Day Low/High 7.19 / 7.63
52 Wk Low/High 2.14 / 12.20
Volume 718.38K
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 44.70M
Market Cap 337.48M
EPS -12.90
Div & Yield N.A. (N.A)

Latest News

Tandem Diabetes Care Applies For Health Canada Medical Device License

Tandem Diabetes Care Applies For Health Canada Medical Device License

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced its submission of a medical device license application to Health Canada to...

Tandem Diabetes Care And Rubin Medical Announce Agreement For Distribution Of Insulin Pump Products In Scandinavia

Tandem Diabetes Care And Rubin Medical Announce Agreement For Distribution Of Insulin Pump Products In Scandinavia

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution...

Reduced Time In Hypoglycemia Demonstrated In Tandem Diabetes Care's Pivotal Trial For The T:slim X2 Insulin Pump With Predictive Low Glucose Suspend Feature; Data To Be Presented At ATTD 2018 Conference

Reduced Time In Hypoglycemia Demonstrated In Tandem Diabetes Care's Pivotal Trial For The T:slim X2 Insulin Pump With Predictive Low Glucose Suspend Feature; Data To Be Presented At ATTD 2018 Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced positive results from a pivotal study of the...

Tandem Diabetes Care Schedules Fourth Quarter And Full Year 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care Schedules Fourth Quarter And Full Year 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its fourth quarter and full year 2017 results...

Tandem Diabetes Care Announces Closing Of $69 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care Announces Closing Of $69 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care ®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the closing of its previously announced...

Tandem Diabetes Care Announces Pricing Of $60 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care Announces Pricing Of $60 Million Underwritten Public Offering Of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering...

Tandem Diabetes Care Announces Preliminary 2017 Results And Provides 2018 Guidance

Tandem Diabetes Care Announces Preliminary 2017 Results And Provides 2018 Guidance

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for...

Tandem Diabetes Care Reports Successful Completion Of First Pilot Study Using T:slim X2 Insulin Pump With TypeZero Hybrid Closed Loop Technology And Dexcom G6 Integration; Confirms IDCL Multi-site Study Timeline

Tandem Diabetes Care Reports Successful Completion Of First Pilot Study Using T:slim X2 Insulin Pump With TypeZero Hybrid Closed Loop Technology And Dexcom G6 Integration; Confirms IDCL Multi-site Study Timeline

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported the successful completion of the first pilot...

Tandem Diabetes Care Commences Full Manufacturing Operations At New San Diego Facility

Tandem Diabetes Care Commences Full Manufacturing Operations At New San Diego Facility

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the commencement of full manufacturing...

Tandem Diabetes Care Announces Issuance Of Patent Related To Automated Insulin Delivery Technology

Tandem Diabetes Care Announces Issuance Of Patent Related To Automated Insulin Delivery Technology

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.

Tandem Diabetes Care Announces Retirement Of CFO And Successor Appointment

Tandem Diabetes Care Announces Retirement Of CFO And Successor Appointment

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the retirement of its executive vice president and chief financial officer (CFO), John Cajigas, effective December 31, 2017.

Tandem Diabetes Care To Present At The 29th Annual Piper Jaffray Healthcare Conference

Tandem Diabetes Care To Present At The 29th Annual Piper Jaffray Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will...

Tandem Diabetes Care To Present At The Stifel 2017 Healthcare Conference

Tandem Diabetes Care To Present At The Stifel 2017 Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will...

Human Factors Research Presented At DTM 2017 Demonstrates Ease Of Use And Effectiveness Of Computer-Based Training For Touchscreen Insulin Pump With Automated Insulin Delivery Feature

Human Factors Research Presented At DTM 2017 Demonstrates Ease Of Use And Effectiveness Of Computer-Based Training For Touchscreen Insulin Pump With Automated Insulin Delivery Feature

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today presented results from a Human Factors study conducted...

Tandem Diabetes Care Reports Third Quarter 2017 Financial Results

Tandem Diabetes Care Reports Third Quarter 2017 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended...

Tandem Diabetes Care To Provide All T:slim X2 Insulin Pump Features Approved In 2018 To Users At No Cost And Expands Existing Dexcom Welcome Offer For Animas Customers

Tandem Diabetes Care To Provide All T:slim X2 Insulin Pump Features Approved In 2018 To Users At No Cost And Expands Existing Dexcom Welcome Offer For Animas Customers

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it will make any new features approved...

Tandem Diabetes Care Schedules Third Quarter 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care Schedules Third Quarter 2017 Earnings Press Release And Conference Call

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its third quarter 2017 results after the...

Tandem Diabetes Care Announces Pricing Of $16.2 Million Underwritten Public Offering Of Common Stock And Warrants

Tandem Diabetes Care Announces Pricing Of $16.2 Million Underwritten Public Offering Of Common Stock And Warrants

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering...

Tandem Diabetes Care Announces Proposed Underwritten Public Offering Of Common Stock, Series A Warrants And Series B Warrants

Tandem Diabetes Care Announces Proposed Underwritten Public Offering Of Common Stock, Series A Warrants And Series B Warrants

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it is proposing to offer and sell shares...

Tandem Diabetes Care Announces Approval Of Reverse Stock Split

Tandem Diabetes Care Announces Approval Of Reverse Stock Split

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) previously announced that a proposal was approved at its Special Meeting of Stockholders, held September 7, 2017, authorizing its Board of Directors to amend the Company's...

Tandem Diabetes Care Reports Rapid Uptake And High Satisfaction Scores For T:slim X2 Insulin Pump Remote Software Update Following Launch Of CGM Integration

Tandem Diabetes Care Reports Rapid Uptake And High Satisfaction Scores For T:slim X2 Insulin Pump Remote Software Update Following Launch Of CGM Integration

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that one-third of t:slim X2™ Pump users...

Tandem Diabetes Care Announces FDA Approval And Launch Of T:slim X2 Insulin Pump With Dexcom G5 Mobile CGM Integration

Tandem Diabetes Care Announces FDA Approval And Launch Of T:slim X2 Insulin Pump With Dexcom G5 Mobile CGM Integration

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.

Tandem Diabetes Care Announces Issuance Of Patent Related To Remote Bolus Feature For Medical Infusion Pumps

Tandem Diabetes Care Announces Issuance Of Patent Related To Remote Bolus Feature For Medical Infusion Pumps

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.

Tandem Diabetes Care Announces Launch Of T:lock Connector For Its Insulin Pump Cartridges And Infusion Sets

Tandem Diabetes Care Announces Launch Of T:lock Connector For Its Insulin Pump Cartridges And Infusion Sets

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the launch of the t:lock™ Connector for...

Tandem Diabetes Care Begins Enrollment In Pivotal Trial For First Touchscreen Insulin Pump With Predictive Low Glucose Suspend (PLGS)

Tandem Diabetes Care Begins Enrollment In Pivotal Trial For First Touchscreen Insulin Pump With Predictive Low Glucose Suspend (PLGS)

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced enrollment of the first patients in an at-home...

Tandem Diabetes Care Announces Issuance Of Patent Related To Important Safety Features For Portable Infusion Pumps That Utilize Touchscreen Control

Tandem Diabetes Care Announces Issuance Of Patent Related To Important Safety Features For Portable Infusion Pumps That Utilize Touchscreen Control

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.

Tandem Diabetes Care To Present At The 2017 Wedbush PacGrow Healthcare Conference

Tandem Diabetes Care To Present At The 2017 Wedbush PacGrow Healthcare Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will...

TheStreet Quant Rating: D- (Sell)